

**TOXICOLOGICAL PROFILE FOR
MANGANESE**

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry

September 2000

DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

UPDATE STATEMENT

A Toxicological Profile for manganese was released in July 1992. This edition supersedes any previously released draft or final profile.

Toxicological Profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology/Toxicology Information Branch
1600 Clifton Road NE, E-29
Atlanta, Georgia 30333

FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.


The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Jeffrey P. Koplan, M.D., M.P.H.
Administrator
Agency for Toxic Substances and
Disease Registry

*Legislative Background

The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed ATSDR to prepare toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. The availability of the revised priority list of 275 hazardous substances was announced in the *Federal Register* on October 21, 1999 (64 FR 56792). For prior versions of the list of substances, see *Federal Register* notices dated April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); February 28, 1994 (59 FR 9486); April 29, 1996 (61 FR 18744); and November 17, 1997 (62 FR 61332). Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list.

QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions.

Primary Chapters/Sections of Interest

Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance's relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

Chapter 2: Health Effects: Specific health effects of a given hazardous compound are reported by *route of exposure*, by *type of health effect* (death, systemic, immunologic, reproductive), and by *length of exposure* (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

NOTE: Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

Pediatrics: Four new sections have been added to each Toxicological Profile to address child health issues:

Section 1.6	How Can Manganese Affect Children?
Section 1.7	How Can Families Reduce the Risk of Exposure to Manganese?
Section 2.6	Children's Susceptibility
Section 5.6	Exposures of Children

Other Sections of Interest:

Section 2.8	Biomarkers of Exposure and Effect
Section 2.11	Methods for Reducing Toxic Effects

ATSDR Information Center

Phone: 1-800-447-1544 (to be replaced by 1-888-42-ATSDR in 1999)
or 404-639-6357

Fax: 404-639-6359

E-mail: atsdric@cdc.gov

Internet: <http://atsdr1.atsdr.cdc.gov:8080>

The following additional material can be ordered through the ATSDR Information Center:

Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an exposure history and how to conduct one are described, and an example of a thorough exposure history is provided. Other case studies of interest include *Reproductive and Developmental Hazards*; *Skin Lesions and Environmental Exposures*; *Cholinesterase-Inhibiting Pesticide Toxicity*; and numerous chemical-specific case studies.

Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—*Medical Management Guidelines for Acute Chemical Exposures*—is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. *Contact:* NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. *Contact:* NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH.

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. *Contact:* NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

Referrals

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. *Contact:* AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: aoec@dgs.dgsys.com • AOEC Clinic Director: <http://occ-env-med.mc.duke.edu/oem/aoec.htm>.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. *Contact:* ACOEM, 55 West Seegers Road, Arlington Heights, IL 60005 • Phone: 847-228-6850 • FAX: 847-228-1856.

CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHOR(S):

Mildred Williams-Johnson, Ph.D., D.A.B.T.
ATSDR, Division of Toxicology, Atlanta, GA

Kara B. Altshuler, Ph.D.
Sciences International, Inc., Alexandria, VA

Steven W. Rhodes, Ph.D.
Laura Kolb, M.P.H.
Sciences International, Inc., Alexandria, VA

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Research Implementation Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.

PEER REVIEW

A peer review panel was assembled for manganese. The panel consisted of the following members:

1. Michael Aschner, Professor, Wake Forest University School of Medicine, Medical Center Building, Winston-Salem, NC 27151
2. Christopher Newland, Professor, Auburn University, Department of Psychology, 110 Thach Hall, Auburn, AL 36849-5212
3. Donna Mergler, Professor, CINBOISE, Universite du Quebec a Montreal, CP 8888, Succ Centreville, Montreal, Quebec, H3C 3P8, Canada
4. Joseph Zayed, Professor, University of Montreal, Faculty of Medicine, Department of Occupational & Environmental Health, TOXHUM (Human Toxicology Research Group), 2375 Cote Ste. Catherine, Montreal, Quebec, H3C 3J7, Canada

These experts collectively have knowledge of manganese's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

CONTENTS

FOREWORD	v
QUICK REFERENCE FOR HEALTH CARE PROVIDERS	vii
CONTRIBUTORS	ix
PEER REVIEW	xi
LIST OF FIGURES	xvii
LIST OF TABLES	xix
1. PUBLIC HEALTH STATEMENT	1
1.1 WHAT IS MANGANESE?	2
1.2 WHAT HAPPENS TO MANGANESE WHEN IT ENTERS THE ENVIRONMENT?	3
1.3 HOW MIGHT I BE EXPOSED TO MANGANESE?	4
1.4 HOW CAN MANGANESE ENTER AND LEAVE MY BODY?	5
1.5 HOW CAN MANGANESE AFFECT MY HEALTH?	6
1.6 HOW CAN MANGANESE AFFECT CHILDREN?	10
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO MANGANESE?	13
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO MANGANESE?	14
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?	16
1.10 WHERE CAN I GET MORE INFORMATION?	17
2. HEALTH EFFECTS	19
2.1 INTRODUCTION	19
2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE	21
2.2.1 Inhalation Exposure	24
2.2.1.1 Death	25
2.2.1.2 Systemic Effects	26
2.2.1.3 Immunological and Lymphoreticular Effects	48
2.2.1.4 Neurological Effects	49
2.2.1.5 Reproductive Effects	65
2.2.1.6 Developmental Effects	67
2.2.1.7 Genotoxic Effects	68
2.2.1.8 Cancer	69
2.2.2 Oral Exposure	69
2.2.2.1 Death	97
2.2.2.2 Systemic Effects	99
2.2.2.3 Immunological and Lymphoreticular Effects	113
2.2.2.4 Neurological Effects	114
2.2.2.5 Reproductive Effects	127
2.2.2.6 Developmental Effects	133

2.2.2.7	Genotoxic Effects	141
2.2.2.8	Cancer	142
2.2.3	Dermal Exposure	143
2.2.3.1	Death	147
2.2.3.2	Systemic Effects	148
2.2.3.3	Immunological and Lymphoreticular Effects	157
2.2.3.4	Neurological Effects	158
2.2.3.5	Reproductive Effects	159
2.2.3.6	Developmental Effects	159
2.2.3.7	Genotoxic Effects	162
2.2.3.8	Cancer	162
2.2.4	DIAGNOSTIC USES	164
2.2.4.1	Death	164
2.2.4.2	Systemic Effects	166
2.2.4.3	Immunological and Lymphoreticular Effects	170
2.2.4.4	Neurological Effects	171
2.2.4.5	Reproductive Effects	172
2.2.4.6	Developmental Effects	173
2.2.4.7	Genotoxic Effects	175
2.3	TOXICOKINETICS	175
2.3.1	Absorption	176
2.3.1.1	Inhalation Exposure	176
2.3.1.2	Oral Exposure	177
2.3.1.3	Dermal Exposure	182
2.3.2	Distribution	182
2.3.2.1	Inhalation Exposure	187
2.3.2.2	Oral Exposure	189
2.3.2.3	Dermal Exposure	193
2.3.2.4	Other Routes of Exposure	193
2.3.3	Metabolism	199
2.3.4	Excretion	203
2.3.4.1	Inhalation Exposure	203
2.3.4.2	Oral Exposure	204
2.3.4.3	Dermal Exposure	207
2.3.4.4	Other Routes of Exposure	207
2.3.5	Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	208
2.4	MECHANISMS OF ACTION	210
2.4.1	Pharmacokinetic Mechanisms	210
2.4.2	Mechanisms of Toxicity	214
2.4.3	Animal-to-Human Extrapolations	219
2.5	RELEVANCE TO PUBLIC HEALTH	221
2.6	CHILDREN'S SUSCEPTIBILITY	266
2.7	ENDOCRINE DISRUPTION	278
2.8	BIOMARKERS OF EXPOSURE AND EFFECT	280
2.8.1	Biomarkers Used to Identify or Quantify Exposure to Manganese	281
2.8.2	Biomarkers Used to Characterize Effects Caused by Manganese	286
2.9	INTERACTIONS WITH OTHER SUBSTANCES	288
2.10	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	290

2.11	METHODS FOR REDUCING TOXIC EFFECTS	295
2.11.1	Reducing Peak Absorption Following Exposure	295
2.11.2	Reducing Body Burden	296
2.11.3	Interfering with the Mechanism of Action for Toxic Effects	297
2.12	ADEQUACY OF THE DATABASE	298
2.12.1	Existing Information on Health Effects of Manganese	299
2.12.2	Identification of Data Needs	302
2.12.3	Ongoing Studies	317
3.	CHEMICAL AND PHYSICAL INFORMATION	321
3.1	CHEMICAL IDENTITY	321
3.2	PHYSICAL AND CHEMICAL PROPERTIES	321
4.	PRODUCTION, IMPORT, EXPORT, USE, AND DISPOSAL	329
4.1	PRODUCTION	329
4.2	IMPORT/EXPORT	334
4.3	USE	336
4.4	DISPOSAL	338
5.	POTENTIAL FOR HUMAN EXPOSURE	339
5.1	OVERVIEW	339
5.2	RELEASES TO THE ENVIRONMENT	341
5.2.1	Air	346
5.2.2	Water	349
5.2.3	Soil	350
5.3	ENVIRONMENTAL FATE	351
5.3.1	Transport and Partitioning	351
5.3.2	Transformation and Degradation	353
5.3.2.1	Air	353
5.3.2.2	Water	354
5.3.2.3	Sediment and Soil	355
5.4	LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	356
5.4.1	Air	356
5.4.2	Water	359
5.4.3	Sediment and Soil	360
5.4.4	Other Environmental Media	361
5.5	GENERAL POPULATION AND OCCUPATIONAL EXPOSURE	364
5.6	EXPOSURES OF CHILDREN	368
5.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	371
5.8	ADEQUACY OF THE DATABASE	373
5.8.1	Identification of Data Needs	373
5.8.2	Ongoing Studies	378
6.	ANALYTICAL METHODS	379
6.1	BIOLOGICAL MATERIALS	380
6.2	ENVIRONMENTAL SAMPLES	385
6.3	ADEQUACY OF THE DATABASE	389
6.3.1	Identification of Data Needs	395

6.3.2 Ongoing Studies	396
7. REGULATIONS AND ADVISORIES	397
8. REFERENCES	403
9. GLOSSARY	463
APPENDICES	
A. ATSDR MINIMAL RISK LEVELS AND WORKSHEET	A-1
B. USER'S GUIDE	B-1
C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS	C-1

LIST OF FIGURES

2-1	Levels of Significant Exposure to Inorganic Manganese—Inhalation	35
2-2	Levels of Significant Exposure to Inorganic Manganese—Oral	81
2-3	Levels of Significant Exposure to Organic Manganese—MMT—Oral	87
2-4	Levels of Significant Exposure to Organic Manganese—Maneb and Mancozeb—Oral	95
2-5	Metabolism of MnDPDP	202
2-6	Qualitative Physiologically Based Pharmacokinetic (PBPK) Model for Manganese	211
2-7	Existing Information on Health Effects of Inorganic Manganese	300
2-8	Existing Information on Health Effects of Organic Manganese	301
5-1	Frequency of NPL Sites with Manganese Contamination	340

LIST OF TABLES

2-1	Levels of Significant Exposure to Inorganic Manganese—Inhalation	27
2-2	Levels of Significant Exposure to Inorganic Manganese—Oral	70
2-3	Levels of Significant Exposure to Organic Manganese—MMT—Oral	85
2-4	Levels of Significant Exposure to Organic Manganese—Maneb and Mancozeb—Oral	89
2-5	Levels of Significant Exposure to Organic Manganese—Maneb and Mancozeb—Dermal	144
2-6	Manganese Levels in Human and Animal Tissues	185
2-7	Manganese Levels in Human Serum/Plasma	186
2-8	Manganese Levels in Rat Tissue after Oral Exposure	191
2-9	Levels of Manganese in Exposed and Non-Exposed Workers	205
2-10	Genotoxicity of Manganese <i>In Vitro</i>	260
2-11	Genotoxicity of Manganese <i>In Vivo</i>	264
2-12	Ongoing Studies on Manganese	318
3-1	Chemical Identity of Manganese and Compounds	322
3-2	Physical and Chemical Properties of Manganese and Compounds	325
4-1	Facilities that Manufacture or Process Manganese	330
4-2	Facilities that Manufacture or Process Maneb	333
5-1	Releases to the Environment from Facilities that Manufacture or Process Manganese	342
5-2	Releases to the Environment from Facilities that Manufacture or Process Maneb	345
5-3	Average Levels of Manganese in Ambient Air	357
5-4	Manganese Concentrations in Selected Foods	362
5-5	Summary of Typical Human Exposure to manganese	365
6-1	Analytical Methods for Determining Manganese in Biological Materials	382
6-2	Analytical Methods for Determining Manganese in Environmental Samples	390
7-1	Regulations and Guidelines Applicable to Manganese	398